Suppr超能文献

儿科癌症患者中万古霉素的药代动力学及预测剂量需求

Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.

作者信息

Abdel Hadi Ola, Al Omar Suha, Nazer Lama H, Mubarak Sawsan, Le Jennifer

机构信息

Novartis, Medical Affairs Department, Amman, Jordan.

Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan

出版信息

J Oncol Pharm Pract. 2016 Jun;22(3):448-53. doi: 10.1177/1078155215591386. Epub 2015 Jun 15.

Abstract

PURPOSE

To determine the pharmacokinetic parameters and compare pharmacodynamic target attainment at different dosing strategies of vancomycin in pediatric cancer patients.

METHODS

Pediatric patients who received vancomycin and had at least two steady-state concentrations taken within the same dosing interval were identified. Vancomycin minimum inhibitory concentrations (MICs) for methicillin resistant staphylococcus aureus (MRSA) isolates from our institution were determined using E-test. The population-based pharmacokinetic modeling was performed using NONMEM 7.2. A one-compartment model with first-order kinetics was used to estimate clearance (CL) and volume of distribution (Vd). Monte Carlo simulations (N = 9800) were performed to compare area-under-the-curve over 24 h (AUC24)/MIC and trough concentration at different doses.

RESULTS

Forty-nine patients, with 120 vancomcyin serum concentrations, were included in the analysis, mean age was 6 ± 2.5 (SD) years, mean weight was 19.6 ± 6.9(SD) kg, mean baseline serum creatinine was 0.4 ± 0.11(SD) mg/dl, and mean initial vancomycin dose was 205 mg/day (range 100-460). Final model pharmacokinetic parameters were: CL (L/h) = 0.381 × weight(0.75) and Vd (L) = 0.663 × weight. Mean baseline (±SD) vancomycin CL was 0.20 ± 0.07 L/h/kg and Vd 0.66 ± 0.001 L/kg. . Renal function, sex, age, stay in the intensive care unit, and co-administration of nephrotoxic medications did not have an effect on the calculated parameters. Using Monte Carlo simulation with reported MICs, a dose of 60 mg/kg/day achieved AUC24/MIC ≥400 and trough concentration ≥15 mcg/mL in only 21.5% and 11% of virtual subjects, respectively.

CONCLUSIONS

Higher than usual vancomycin doses may be required to treat serious MRSA infections in pediatric patients. The currently recommended dose of 60 mg/kg/day is unlikely to achieve the targets in most subjects. The optimal vancomycin dosing in pediatric cancer patients requires further investigations.

摘要

目的

确定儿科癌症患者中万古霉素不同给药策略的药代动力学参数,并比较药效学目标达成情况。

方法

识别出接受万古霉素治疗且在同一给药间隔内至少采集了两次稳态血药浓度的儿科患者。使用E-test法测定我院耐甲氧西林金黄色葡萄球菌(MRSA)分离株的万古霉素最低抑菌浓度(MIC)。采用NONMEM 7.2进行基于群体的药代动力学建模。使用具有一级动力学的单室模型来估计清除率(CL)和分布容积(Vd)。进行蒙特卡洛模拟(N = 9800)以比较不同剂量下24小时曲线下面积(AUC24)/MIC和谷浓度。

结果

49例患者纳入分析,共120次万古霉素血药浓度,平均年龄6±2.5(标准差)岁,平均体重19.6±6.9(标准差)kg,平均基线血清肌酐0.4±0.11(标准差)mg/dl,平均初始万古霉素剂量205 mg/天(范围100 - 460)。最终模型的药代动力学参数为:CL(L/h)= 0.381×体重(0.75),Vd(L)= 0.663×体重。平均基线(±标准差)万古霉素CL为0.20±0.07 L/h/kg,Vd为0.66±0.001 L/kg。肾功能、性别、年龄、入住重症监护病房情况以及肾毒性药物的联合使用对计算参数均无影响。根据报道的MIC进行蒙特卡洛模拟,60 mg/kg/天的剂量在仅21.5%的虚拟受试者中达到AUC24/MIC≥400,在仅11%的虚拟受试者中达到谷浓度≥15 mcg/mL。

结论

治疗儿科患者严重MRSA感染可能需要高于常规的万古霉素剂量。目前推荐的60 mg/kg/天剂量在大多数受试者中不太可能达到目标。儿科癌症患者中万古霉素的最佳给药方案需要进一步研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验